Frederik Hoogwater

Dr. Frederik Hoogwater is an active researcher at the University of Groningen's Faculty of Medical Sciences, Department of Surgery, specializing in hepatobiliary oncology and surgical interventions for biliary tract cancers. His work primarily focuses on cholangiocarcinoma treatment, surgical resection techniques, and cancer outcomes research through the University Medical Center Groningen (UMCG).

His research interests center on surgical oncology with particular expertise in cholangiocarcinoma (94% of his research fingerprint), neoplasms (64%), gallbladder cancer (61%), and hepatectomy procedures (48%). Dr. Hoogwater investigates critical aspects including resection techniques, recurrent disease management, and overall survival metrics in hepato-pancreato-biliary malignancies, contributing significantly to the understanding of perihilar cholangiocarcinoma classification and treatment protocols.

Analysis of his recent publications reveals a strong trend toward multicenter clinical research, particularly in developing consensus guidelines for cholangiocarcinoma management and evaluating innovative surgical and endoscopic approaches. His work spans surgical techniques, cancer biology, and population health studies, with increasing focus on immunotherapeutic targets and lifestyle factors affecting cancer outcomes. Current research directions include evaluating new resectability classifications through Delphi methodology, comparing biliary drainage techniques, and investigating immunotherapeutic targets like Gal-9 in pancreatic cancer.

Dr. Hoogwater has contributed to 70 research outputs including 60 articles, 8 review articles, 1 editorial, and 1 erratum. His collaborative network spans international institutions, with significant multicenter work on perihilar cholangiocarcinoma through the Perihilar Cholangiocarcinoma Collaboration Group. Recent projects include a 2021 study at UMCG Groningen investigating cannabis oil for advanced liver cancer patients and multiple prospective studies examining surgical outcomes and novel therapeutic approaches in biliary tract cancers.